Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

被引：43
|
作者：
Mangen, Marie-Josee J. [1 ,2 ]
van Duynhoven, Yvonne T. H. P. [2 ]
Vennema, Harry [2 ]
van Pelt, Wilfrid [2 ]
Havelaar, Arie H. [2 ,3 ]
de Melker, Hester E. [2 ]
机构：
[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[2] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands
[3] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands
来源：
VACCINE | 2010年 / 28卷 / 14期
关键词：
Rotavirus vaccination; National immunization program; Cost-effectiveness; RISK-FACTORS; DISEASE BURDEN; GASTROENTERITIS; ENGLAND; HOSPITALIZATIONS; NETHERLANDS; INFECTIONS; EFFICACY; INFANTS; CAMPYLOBACTER;
D O I：
10.1016/j.vaccine.2010.01.014
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix (R) is more cost-effective than RotaTeq (R), resulting in a cost-utility ratio (CUR) of (sic) 53,000 per DALY (third payer perspective) and (sic) 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2624 / 2635
页数：12
相关论文
共 50 条
  • [41] Varicella vaccination in adults: Is it cost-effective? Editorial commentary
    Lee, Grace M.
    CLINICAL INFECTIOUS DISEASES, 2007, 44 (08) : 1049 - 1050
  • [42] Is herpes zoster vaccination likely to be cost-effective in Canada?
    Peden, Alexander D.
    Strobel, Stephenson B.
    Forget, Evelyn L.
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2014, 105 (04): : E287 - E295
  • [43] Cost Analysis of a PTO Driveline Shielding Program: Are Effective Programs Cost-Effective?
    Tinc, Pamela J.
    Sorensen, Julie A.
    Jenkins, Paul L.
    Kelsey, Timothy
    JOURNAL OF AGRICULTURAL SAFETY AND HEALTH, 2021, 27 (04): : 205 - 214
  • [44] An approach to finding the cost-effective immunization targets for information assurance
    Liu, Guannan
    Zhang, Jin
    Chen, Guoqing
    DECISION SUPPORT SYSTEMS, 2014, 67 : 40 - 52
  • [45] Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program
    Flannery, Brendan
    Samad, Samia
    de Moraes, Jose Cassio
    Tate, Jacqueline E.
    Danovaro-Holliday, M. Carolina
    de Oliveira, Lucia Helena
    Rainey, Jeanette J.
    VACCINE, 2013, 31 (11) : 1523 - 1528
  • [46] Is a catch-up hepatitis B vaccination campaign in Dutch high-risk adults cost-effective?
    de Wit, G. A.
    Kretzschmar, M.
    Mangen, M. J. J.
    van de Laar, M. J. W.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2006, 16 : 52 - 52
  • [47] COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION IMPLEMENTATION IN OLDER ADULT IMMUNIZATION SCHEDULE IN THE BRAZILIAN NATIONAL PROGRAM
    Parellada, C.
    Riveros, B. S.
    Moreira, T. N. F.
    Deb, A.
    Owusu-Edusei, K.
    Yande, S.
    Chitale, R.
    Johnson, K. D.
    VALUE IN HEALTH, 2022, 25 (07) : S375 - S375
  • [48] Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
    Zeevat, Florian
    Crepey, Pascal
    Dolk, F. Christiaan K.
    Postma, Arjan J.
    Breeveld-Dwarkasing, Vidya N. A.
    Postma, Maarten J.
    VALUE IN HEALTH, 2021, 24 (01) : 3 - 10
  • [49] COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM
    Zeevat, F.
    Crepey, P.
    Dolk, C.
    Postma, A. J.
    Breeveld-Dwarkasing, V. N. A.
    Postma, M.
    VALUE IN HEALTH, 2019, 22 : S647 - S647
  • [50] Distribution of Rotavirus Genotypes After Introduction of Rotavirus Vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia
    Kirkwood, Carl D.
    Boniface, Karen
    Barnes, Graeme L.
    Bishop, Ruth F.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (01) : S48 - S53
12345